Studier
Studier med Aklief visar synliga förändringar i ansiktet och på bålen2:
Signifikant förbättring av ansiktsakne och bålakne för patienter vid vecka 12 jämfört med utgångsvärdet2
Referenser:
*p<0.001 (significant treatment difference vs vehicle); PIVOTAL studies 1 and 2 were identically designed, large-scale randomised Phase 3 trials, simultaneously evaluating the efficacy, safety and tolerability of AKLIEF Cream in 2,420 patients with both facial and truncal acne.
† Mean absolute change in reduction in total facial/truncal lesion counts from baseline.
2. Tan J, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol 2019;80(6):1691–99
Aklief ger förbättringar i ansiktet och på bålen under 12 månader3:
Adapted from Blume-Peytavi et al. 2020. Longterm data on saftey and efficacy of AKLIEF cream, open label, 52 weeks in 453 patients with both truncal and facial acne.
The study included patients 9 years of age or older at enrolment, with an Investigator Global Assessment (IGA, for face) and Physician’s Global Assessment (PGA for trunk) score of 3 (moderate) on a 5-point scale (from 0 = clear to 4 = severe)
Success rate on efficacy was measured on “clear=0” or “almost Clear=1”
Referenser:
3. Blume-Peytavi U, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol 2020;34(1):166–73